Quick Answer
Axsome Therapeutics, Inc. reported Long-Term Debt of $117.75 million for fiscal year 2025.
Axsome Therapeutics, Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2025 | $117.75M | -34.8% |
| 2024 | $180.71M | +1.5% |
| 2023 | $178.07M | +88.9% |
| 2022 | $94.26M | +92.0% |
| 2021 | $49.09M | +1.6% |
| 2020 | $48.32M | +178.8% |
| 2019 | $17.33M | +378.9% |
| 2018 | $3.62M | -45.7% |
| 2017 | $6.66M | -29.6% |
| 2016 | $9.47M | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $117.64M | -34.6% | +0.1% |
| June 30, 2025 | $117.54M | -34.5% | -35.2% |
| March 31, 2025 | $181.38M | +1.5% | +0.4% |
| December 31, 2024 | $180.71M | +1.5% | +0.4% |
| September 30, 2024 | $180.00M | +1.4% | +0.4% |
| June 30, 2024 | $179.33M | +1.4% | +0.4% |
| March 31, 2024 | $178.69M | +21.1% | +0.3% |
| December 31, 2023 | $178.07M | +88.9% | +0.4% |
- Axsome Therapeutics, Inc. showed a decrease of -34.8% in Long-Term Debt compared to the prior fiscal year.
- Over the 2016–2025 period, Axsome Therapeutics, Inc.’s long-term debt has grown by 1143.3% (from $9.47 million to $117.75 million).
- The most recent figure is from Axsome Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: